Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab (Herceptin©), Yale School of Medicine researchers report in the current issue of the Journal of the American College of Cardiology.
The researchers conducted this study because older women who are at higher risk of decreased heart function, were often excluded from randomized clinical trials of trastuzumab, which is used to treat breast tumors that over-express human epidermal growth factor receptor-2 (HER-2). Past clinical trials in younger, healthier women showed improved survival, but also increased heart complications linked to trastuzumab, especially when combined with a frequently used therapy called anthracycline chemotherapy.
"We observed an even higher risk of heart failure or cardiomyopathy after trastuzumab therapy than those in past clinical trials," said lead author Jersey Chen, M.D., assistant professor of cardiology at Yale University School of Medicine and a member of the Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale.
The Yale COPPER team examined the association between the use of adjuvant trastuzumab and anthracycline therapy and heart failure and cardiomyopathy, the most serious cardiotoxic complications, in 45,536 female Medicare beneficiaries with early-stage breast cancer. The use of trastuzumab has increased over time from 2.6% of the women who received any adjuvant therapy in 2000 to 22.6% in 2007.
The team found that compared with patients who received no adjuvant chemotherapy or trastuzumab; use of trastuzumab was associated with a 14% higher adjusted incidence rate for heart failure or cardiomyopathy over three years. Patients who received both trastuzumab and anthracycline had a 23.8% higher rate, and those treated with anthracycline chemotherapy alone had a 2.1% higher rate of heart failure or cardiomyopathy events over three years.
"Further study is needed to fully understand the benefits and risks of trastuzamab when they are used in the real-world population," said Cary Gross, senior author of the study and director of the COPPER Center.
Yale University: http://www.yale.edu
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Leading scientists say spread of artemisinin-resistant parasites to Africa could prove disastrous
The health of infants is being put at risk as anti-vaccine groups discourage uptake of vitamin K for newborns, says Amanda Marcott
The lead in human teeth holds clues about where a person grew up and can help criminal investigators and archaeologists working with old or decomposed corpses, according to a University of Florida researcher.
West African countries are trying to contain the deadly disease
The Great War helped create the influenza pandemic of 1918, which eventually brought an early end to the Great War.
In 1986, a two-and-a-half year-old girl named Michelle Funk fell into a stream and drowned. By the time paramedics found her, she hadn’t been breathing for more than an hour. Her heart was stopped. In other words, she was dead.
Political unrest in Pakistan has been a gift to the poliovirus, with 99 cases reported there so far this year. But Rotary International, which has already vaccinated 2 billion children in 122 countries, is hitting back hard
UK scientists model the physical attributes that underpin our social judgements about strangers.
A new study suggests that using media technology may be the wrong way to try to unwind at the end of a hard day
Arizona death row inmate Joseph Wood took almost 2 hours to die – why is a drug combination is being experimented with in the death chamber?